Role of triglycerides as a predictor of autoimmune hepatitis with cirrhosis

[1]  S. Kakar,et al.  Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[2]  M. Manns,et al.  Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. , 2022, Journal of hepatology.

[3]  Ming Cai,et al.  Association of Low High-Density Lipoprotein Cholesterol Levels with Poor Outcomes in Hepatitis B-Associated Decompensated Cirrhosis Patients , 2021, BioMed research international.

[4]  A. Mancuso,et al.  Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis , 2021, Postgraduate medicine.

[5]  K. Lindor,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis , 2021, Hepatology International.

[6]  Xiaoyuan Xu,et al.  High-density lipoprotein cholesterol is a predictor of survival in cirrhotic patients with acute gastrointestinal bleeding: a retrospective study , 2020, BMC Gastroenterology.

[7]  R. Carr,et al.  Alcohol effects on hepatic lipid metabolism , 2020, Journal of Lipid Research.

[8]  M. Trauner,et al.  Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease , 2019, Wiener klinische Wochenschrift.

[9]  G. Kuftinec,et al.  Nutrition in Cirrhosis , 2019, Current Gastroenterology Reports.

[10]  Kisha Mitchell,et al.  Histologic features of autoimmune hepatitis: a critical appraisal. , 2018, Human pathology.

[11]  Yuyong Jiang,et al.  Effect of serum triglyceride level on the prognosis of patients with hepatocellular carcinoma in the absence of cirrhosis , 2018, Lipids in Health and Disease.

[12]  M. Manns,et al.  Autoimmune hepatitis , 2018, Nature Reviews Disease Primers.

[13]  F. Conti,et al.  Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. , 2017, Annals of hepatology.

[14]  L. Holmberg,et al.  The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort , 2017, International journal of cancer.

[15]  M. Gershwin,et al.  The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review , 2017, Clinical Reviews in Allergy & Immunology.

[16]  J. Marrero,et al.  Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. , 2016, Journal of hepatology.

[17]  A. Burls.  Critical appraisal , 2016, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[18]  Z. Abbas,et al.  Autoimmune liver diseases in the Asia–Pacific region: Proceedings of APASL symposium on AIH and PBC 2016 , 2016, Hepatology International.

[19]  Khairy H. Morsya,et al.  Lipid profile among cirrhotic patients with and without hepatocellular carcinoma in Upper Egypt , 2015 .

[20]  R. Flisiak,et al.  The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins , 2013, Clinical and Experimental Medicine.

[21]  Peiyuan Yin,et al.  Serum lipid profiling of patients with chronic hepatitis B, cirrhosis, and hepatocellular carcinoma by ultra fast LC/IT‐TOF MS , 2013, Electrophoresis.

[22]  M. Janíčko,et al.  Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. , 2013, Annals of hepatology.

[23]  E. Fassio,et al.  Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis. , 2012, Annals of hepatology.

[24]  M. Bassendine,et al.  HCV and the hepatic lipid pathway as a potential treatment target. , 2011, Journal of hepatology.

[25]  Y. Shiratori,et al.  A model for estimating cirrhosis in patients with type 1 autoimmune hepatitis , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  K. Boberg,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Simplified Criteria for the Diagnosis of Autoimmune Hepatitis , 2008 .

[27]  A. Czaja,et al.  Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly , 2006, Hepatology.

[28]  T. Arenovich,et al.  Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome , 2005, Hepatology.

[29]  W. Pandak,et al.  High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  W. Kim,et al.  MELD accurately predicts mortality in patients with alcoholic hepatitis , 2005, Hepatology.

[31]  C. Halsted,et al.  Nutrition and Alcoholic Liver Disease , 2004, Seminars in liver disease.

[32]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[33]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.